Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134088

Published: 2020

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression

Heike Schmidlin, Sean A. Diehl, Maho Nagasawa, Ferenc A. Scheeren, Remko Schotte, Christel H. Uittenbogaart, Hergen Spits, Bianca Blom

Blood (2008) 112 (5): 1804–1812.

https://doi.org/10.1182/blood-2008-01-136440

Published: 2008

Includes: Supplemental data

Journal Articles

Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B

Wendy Dontje, Remko Schotte, Tom Cupedo, Maho Nagasawa, Ferenc Scheeren, Ramon Gimeno, Hergen Spits, Bianca Blom

Blood (2006) 107 (6): 2446–2452.

https://doi.org/10.1182/blood-2005-05-2090

Published: 2006

Includes: Supplemental data

Journal Articles

The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development

Remko Schotte, Marie-Clotilde Rissoan, Nathalie Bendriss-Vermare, Jean-Michel Bridon, Thomas Duhen, Kees Weijer, Francine Brière, Hergen Spits

Blood (2003) 101 (3): 1015–1023.

https://doi.org/10.1182/blood-2002-02-0438

Published: 2003

NARROW

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression

Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B

The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development

Email alerts

ASH Publications

American Society of Hematology

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression

Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T-cell lineage decision through control of GATA-3 and Spi-B

The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only